NCT02825628 - Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2020

Conditions

Prostate Cancer Metastatic

Interventions

DRUG

Osteodex

formulation: solution for infusion route of administration: intravenous infusion

Trial Locations (8)

Pauls Strandins Clinical University Hospital, Riga

Latgales Urology Center, Daugavpils

East Tallinn Central Hospital, Tallinn

Tampere University Hospital, Urology Clinic, Tampere

Tartu University Hospital, Tartu

Örebro University Hospital, Örebro

Urology Clinic, Sodersjukhuset AB, Stockholm

Oncology Clinic, Norrlands Universitetssjukhus, Umeå